WO2001085164A1 - The treatment of herpes - Google Patents

The treatment of herpes Download PDF

Info

Publication number
WO2001085164A1
WO2001085164A1 PCT/NZ2001/000086 NZ0100086W WO0185164A1 WO 2001085164 A1 WO2001085164 A1 WO 2001085164A1 NZ 0100086 W NZ0100086 W NZ 0100086W WO 0185164 A1 WO0185164 A1 WO 0185164A1
Authority
WO
WIPO (PCT)
Prior art keywords
cetyl
cetyl myristate
dosage unit
myristate
mixture
Prior art date
Application number
PCT/NZ2001/000086
Other languages
French (fr)
Inventor
Timothy David Meakin
Craig Leonard Heatley
Dianne Cadwallader
Original Assignee
Meracol Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meracol Corporation Limited filed Critical Meracol Corporation Limited
Priority to AU2001260834A priority Critical patent/AU2001260834A1/en
Publication of WO2001085164A1 publication Critical patent/WO2001085164A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • the present invention relates to a method of treatment and/or prophylaxis of at least the symptoms of herpes simplex or related herpes skin ailments.
  • herpes simplex infection can be recognized by the appearance of small, grouped vesicles showing up under the skin as red spots which then become pustules, which ruptures and breaks the skins surface. This then forms a crust on the outside of the skin. The rupturing can cause deep lesions.
  • the present invention has surprisingly determined that the administration (particularly by ingestion) of cetyl myristate, and particularly cetyl myristate in conjunction with cetyl palmitate, provides an effective treatment of at least the symptoms of he ⁇ es simplex and related herpes skin ailments.
  • Cetyl myristate and cetyl palmitate can each be sourced from animals or vegetables. Cetyl myristate is not to be mistaken for cetyl myristoleate which is also a fatty acid derived traditionally from spermaceti by saponification and more recently from the tallow of bovine(s).
  • cetyl myristate has a negligible anti-arthritic activity in laboratory experiments and reference is made to the website www.gcinutrients.com/Newletter.com. However this point is arguable and a product known as cetyl myristate sold by Amerex Corporation of 770 Sycamore Avenue, Suite J148, Vista, CA 92083, USA purports that cetyl myristate is useful for the treatment of arthritis.
  • Cetyl myristate is derived from the saturated fatty acid, myristic acid. This acid is found in nutmeg butter, in the fats of Myristicaceae, in palm seed fats, milk fats and also sperm whale oil. Reference is made to US 2,481,365 which discloses the preparation of myristic acid from tall-oil fatty acids. It is to be noted that Amerex Corporation source the cetyl myristate used in their products from sunflower oil. See their website at www.hollinet.com. Cetyl palmitate is derived from the fatty acid, palmitic acid which occurs as the glycerol ester in many oils and fats such as palm oil or Chinese vegetable tallow.
  • a synthetic method of preparation is to react palmitoyl chloride and cetyl alcohol in the presence of magnesium. See the Merck Index, 12th edition at page 336. Reference is also made to US patent 3,169,099 which discloses a biosynthetic method of producing cetyl palmitate.
  • the present invention is directed to the treatment and/or prophylaxis of at least the symptoms of herpes reliant upon administration (whether by self administration or otherwise) of either cetyl myristate or cetyl myristate and cetyl palmitate (whether given simultaneously in admixture or not or given serially).
  • the present invention also encompasses the prospect of dosage forms that in some instances might contain cetyl myristate alone and in other instances both cetyl myristate and cetyl palmitate and dosage regimes that might use one dosage form or both.
  • the invention is a method of treatment and/or prophylaxis of a mammal for at least the symptoms of herpes simplex which comprises or includes administering or having self administered to such mammal an effective amount of either
  • said administration is orally of (b) whether as a mixture of both cetyl myristate and cetyl palmitate, or serially.
  • the effective amount is of (b).
  • Preferably said administration is with a mixture of cetyl myristate in conjunction with cetyl palmitate where the cetyl myristate comprises from 50 to 98% w/w of the mixture.
  • said effective amount of (a) or (b) is by means of one of more capsules.
  • the method also extends to related conditions, eg; accelerated wound healing where a composition as disclosed in US Patent 4,775,291 can at least sometimes be supplemented by use of the present invention methodology.
  • the invention is an oral pharmaceutical composition for treating he ⁇ es which comprises or includes both cetyl myristate and cetyl palmitate.
  • the invention is an oral pharmaceutical composition for treating he ⁇ es simplex which comprises or includes both cetyl myristate and cetyl palmitate.
  • cetyl myristate comprises at least 50% by weight of the composition.
  • composition also includes at least one pharmaceutically acceptable excipient and/or diluent.
  • the invention is an oral dosage unit effective in the treatment of he ⁇ es simplex, said dosage unit having either
  • said dosage unit has (b) and said cetyl myristate in any such mixture comprises from 50 to 98% w/w of the mixture.
  • the dosage unit has (a) only and there is between 5 to 400 mg of cetyl myristate.
  • (a) or (b) is in a capsule.
  • said capsule also includes a pharmaceutically acceptable excipient and/or diluent.
  • the dosage unit includes silicon dioxide.
  • the dosage unit also contains calcium phosphate and/or magnesium oxide.
  • the dosage unit also includes additionally at one trace element.
  • the invention is a liquid dosage unit being also an oral dosage unit as aforesaid.
  • the invention is the use, in the manufacture of oral dosage units for the treatment or prophylaxis of at least the symptoms of he ⁇ es simplex or related he ⁇ es skin ailments in a mammal, of
  • the invention is the use, in the manufacture of oral dosage units for the treatment or prophylaxis of at least the symptoms of he ⁇ es simplex or related he ⁇ es skin ailments in a mammal, of
  • cetyl palmitate (ii) cetyl palmitate.
  • the mixture can use cetyl myristate available from a commercial source such as EHP Products Inc., PO Box 20727, Mt Pleasant, SC 29465 or at Amerex Co ⁇ oration, 770 Sycamore Avenue Suite J148 Vista, California 92083.
  • the mixture can use cetyl palmitate derived from a source such as, for example, Quimica Croda, S.A. de C.V, Circuito Medicos No.47. Apdo. Postal 71-A Cd. Satelite, 53100 Naucalpan, Edo. de Mexico, Mexico or online at www.butterburandsage.com.
  • a source such as, for example, Quimica Croda, S.A. de C.V, Circuito Medicos No.47. Apdo. Postal 71-A Cd. Satelite, 53100 Naucalpan, Edo. de Mexico, Mexico or online at www.butterburandsage.com.
  • the mixture is synthetised from starting materials utilising the procedures as disclosed in New Zealand Patent Specification No. 332959 which involves reacting both myristic acid and palmitic acid with a cetyl alcohol at an elevated temperature in the presence of at least one acid catalyst and at least one aromatic hydrocarbon.
  • the aromatic hydrocarbon fraction then contains the cetyl myristate and cetyl palmitate from whence it can be crystallised.
  • NZ 332959 The full content of NZ 332959 is here inco ⁇ orated by way of reference.
  • This crystallised form can then be ground up, dissolved and mixed with a suitable general pharmacy liquid to be administered to a person.
  • the crystals are usually dissolved in hot water before adding to the pharmacy liquid which is usually a sugar syrup available from most pharmaceutical companies.
  • the liquid is made up to a concentration of 70 w/v.
  • the crystals may be ground up into a powder and combined with magnesium oxide, silicon oxide and fine di-calcium phosphate. This powder can then be transferred into capsules for oral ingestion into the body.
  • the capsules used are VEGICAPTM that are non-gelatin containing.
  • the mode of administration is preferably oral.
  • the dosage unit can be either a swallowable capsule or some alternative (preferably having the active ingredient(s) as a wax-like solid or can be an orally consumable liquid composition (eg; made up with a general pharmacy type carrier such as methyl cellulose)).
  • Other modes of administration can include transdermal, sublingual, parenteral, and suppository delivery.
  • the oral administration for the treatment of he ⁇ es can be in addition to any other medicament administered for such ailment whether administered orally, topically, parenterally, sublingually, etc.
  • the present invention will involve ideally oral self administration of effective quantities of cetyl myristate alone or more preferably as a mixture of both cetyl myristate and cetyl palmitate.
  • the cetyl myristate comprises at least about half of the mixture or the serial application on a weight to weight basis. It is envisaged that daily doses will vary depending on patient needs and may range from 1 to 20 capsules per day. A capsule ideally contains between 5 to 370 mg of the mixture or cetyl myristate.
  • Patient 1 is female and is 42 years of age.
  • Patient 1 suffers an acute flair of he ⁇ es simplex on her upper lip which results in deep lesions developing on her lip which is triggered by cold wind or sun exposure to her lips. In the past, this patient had used ZOVIRAXTM ointment.
  • Patient 1 was provided with capsules of a dosage unit as described in this invention for a dosage regime of 4 capsules, 3 times daily.
  • Patient 2 is female and is 39 years of age.
  • Patient 2 suffers acute he ⁇ es simplex virus on her lips. Again, this is triggered by cold wind or sun exposure to her lips. Again like patient 1, this patient has used ZOVIRAXTM ointment.
  • Patient 2 was provided with capsules of a dosage unit as described in this invention for a dosage regime of 4 capsules, 3 times daily. After one day the lesion did not develop any further and was also superficial as far as the lesion was concerned. • Patient 3 is male and is 43 years of age.
  • Patient 3 has suffered from He ⁇ es simplex virus for 20 years. The virus attacks when the patient is run down and this is usually every 2-3 months. The symptoms begin with a common, itchy pain on the lip with the development of a lesion that can last up to 10-12 days. His treatment has included taking lysine amino acid as a dietary supplement.
  • Patient 3 was provided with capsules of a dosage unit as described in this invention for a dosage regime of 6 capsules, 3 times daily. This dosage begins when he sees the first symptoms of a he ⁇ es "pimple" and he continues with this dosage until the acute signs have disappeared.

Abstract

The treatment of humans or other mammals for at least the prophylaxis of at least the symptoms of herpes simplex or related herpes skin ailments using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.

Description

THE TREATMENT OF HERPES
TECHNICAL FIELD
The present invention relates to a method of treatment and/or prophylaxis of at least the symptoms of herpes simplex or related herpes skin ailments.
BACKGROUND
Common symptoms of herpes simplex infection can are be recognized by the appearance of small, grouped vesicles showing up under the skin as red spots which then become pustules, which ruptures and breaks the skins surface. This then forms a crust on the outside of the skin. The rupturing can cause deep lesions.
The present invention has surprisingly determined that the administration (particularly by ingestion) of cetyl myristate, and particularly cetyl myristate in conjunction with cetyl palmitate, provides an effective treatment of at least the symptoms of heφes simplex and related herpes skin ailments.
Cetyl myristate and cetyl palmitate can each be sourced from animals or vegetables. Cetyl myristate is not to be mistaken for cetyl myristoleate which is also a fatty acid derived traditionally from spermaceti by saponification and more recently from the tallow of bovine(s).
Reference is made to US Patent No.4,113,881 where it is disclosed that the administration of an effective amount of cetyl myristoleate to a mammal is useful in inhibiting or relieving the symptoms of inflammatory rheumatoid arthritis in mammals. Also in US 5,569,676 there is disclosure of the use of cetyl myristoleate in the treatment of osteo-arthritis.
It is thought that cetyl myristate has a negligible anti-arthritic activity in laboratory experiments and reference is made to the website www.gcinutrients.com/Newletter.com. However this point is arguable and a product known as cetyl myristate sold by Amerex Corporation of 770 Sycamore Avenue, Suite J148, Vista, CA 92083, USA purports that cetyl myristate is useful for the treatment of arthritis.
Cetyl myristate is derived from the saturated fatty acid, myristic acid. This acid is found in nutmeg butter, in the fats of Myristicaceae, in palm seed fats, milk fats and also sperm whale oil. Reference is made to US 2,481,365 which discloses the preparation of myristic acid from tall-oil fatty acids. It is to be noted that Amerex Corporation source the cetyl myristate used in their products from sunflower oil. See their website at www.hollinet.com. Cetyl palmitate is derived from the fatty acid, palmitic acid which occurs as the glycerol ester in many oils and fats such as palm oil or Chinese vegetable tallow. A synthetic method of preparation is to react palmitoyl chloride and cetyl alcohol in the presence of magnesium. See the Merck Index, 12th edition at page 336. Reference is also made to US patent 3,169,099 which discloses a biosynthetic method of producing cetyl palmitate.
It is an objection of the present invention to provide a medicament to aid in the treatment of herpes and at least herpes simplex which will provide an alternative to existing treatments or to provide the public with a useful choice.
DISCLOSURE OF INVENTION
As indicated earlier the present invention is directed to the treatment and/or prophylaxis of at least the symptoms of herpes reliant upon administration (whether by self administration or otherwise) of either cetyl myristate or cetyl myristate and cetyl palmitate (whether given simultaneously in admixture or not or given serially).
The present invention also encompasses the prospect of dosage forms that in some instances might contain cetyl myristate alone and in other instances both cetyl myristate and cetyl palmitate and dosage regimes that might use one dosage form or both.
In another aspect the invention is a method of treatment and/or prophylaxis of a mammal for at least the symptoms of herpes simplex which comprises or includes administering or having self administered to such mammal an effective amount of either
(a) cetyl myristate, or
(b) cetyl myristate and cetyl palmitate.
Preferably said administration is orally of (b) whether as a mixture of both cetyl myristate and cetyl palmitate, or serially.
Preferably the effective amount is of (b).
Preferably said administration is with a mixture of cetyl myristate in conjunction with cetyl palmitate where the cetyl myristate comprises from 50 to 98% w/w of the mixture.
Preferably said effective amount of (a) or (b) is by means of one of more capsules.
The method also extends to related conditions, eg; accelerated wound healing where a composition as disclosed in US Patent 4,775,291 can at least sometimes be supplemented by use of the present invention methodology.
In another aspect the invention is an oral pharmaceutical composition for treating heφes which comprises or includes both cetyl myristate and cetyl palmitate. In still another aspect the invention is an oral pharmaceutical composition for treating heφes simplex which comprises or includes both cetyl myristate and cetyl palmitate.
Preferably said cetyl myristate comprises at least 50% by weight of the composition.
Preferably said composition also includes at least one pharmaceutically acceptable excipient and/or diluent.
In still another aspect the invention is an oral dosage unit effective in the treatment of heφes simplex, said dosage unit having either
(a) cetyl myristate, or
(b) a mixture of cetyl myristate and cetyl palmitate.
Preferably said dosage unit has (b) and said cetyl myristate in any such mixture comprises from 50 to 98% w/w of the mixture.
In another variant the dosage unit has (a) only and there is between 5 to 400 mg of cetyl myristate.
Preferably in the dosage use, where (b) is present, there is from 5 to 400 mg of the mixture of cetyl myristate and cetyl palmitate.
Preferably (a) or (b) is in a capsule.
Preferably said capsule also includes a pharmaceutically acceptable excipient and/or diluent.
Preferably the dosage unit includes silicon dioxide.
Preferably the dosage unit also contains calcium phosphate and/or magnesium oxide.
Preferably the dosage unit also includes additionally at one trace element.
In another aspect the invention is a liquid dosage unit being also an oral dosage unit as aforesaid.
In another aspect the invention is the use, in the manufacture of oral dosage units for the treatment or prophylaxis of at least the symptoms of heφes simplex or related heφes skin ailments in a mammal, of
(a) cetyl myristate, or
(b) a mixture of cetyl myristate and cetyl palmitate, or
(c) cetyl palmitate.
In another aspect the invention is the use, in the manufacture of oral dosage units for the treatment or prophylaxis of at least the symptoms of heφes simplex or related heφes skin ailments in a mammal, of
(i) cetyl myristate and
(ii) cetyl palmitate. The mixture can use cetyl myristate available from a commercial source such as EHP Products Inc., PO Box 20727, Mt Pleasant, SC 29465 or at Amerex Coφoration, 770 Sycamore Avenue Suite J148 Vista, California 92083.
The mixture can use cetyl palmitate derived from a source such as, for example, Quimica Croda, S.A. de C.V, Circuito Medicos No.47. Apdo. Postal 71-A Cd. Satelite, 53100 Naucalpan, Edo. de Mexico, Mexico or online at www.butterburandsage.com.
Most ideally however the mixture is synthetised from starting materials utilising the procedures as disclosed in New Zealand Patent Specification No. 332959 which involves reacting both myristic acid and palmitic acid with a cetyl alcohol at an elevated temperature in the presence of at least one acid catalyst and at least one aromatic hydrocarbon. The aromatic hydrocarbon fraction then contains the cetyl myristate and cetyl palmitate from whence it can be crystallised.
The full content of NZ 332959 is here incoφorated by way of reference.
This crystallised form can then be ground up, dissolved and mixed with a suitable general pharmacy liquid to be administered to a person. The crystals are usually dissolved in hot water before adding to the pharmacy liquid which is usually a sugar syrup available from most pharmaceutical companies. The liquid is made up to a concentration of 70 w/v.
Alternatively the crystals may be ground up into a powder and combined with magnesium oxide, silicon oxide and fine di-calcium phosphate. This powder can then be transferred into capsules for oral ingestion into the body. The capsules used are VEGICAP™ that are non-gelatin containing.
The mode of administration is preferably oral. The dosage unit can be either a swallowable capsule or some alternative (preferably having the active ingredient(s) as a wax-like solid or can be an orally consumable liquid composition (eg; made up with a general pharmacy type carrier such as methyl cellulose)).
Other modes of administration can include transdermal, sublingual, parenteral, and suppository delivery.
The oral administration for the treatment of heφes can be in addition to any other medicament administered for such ailment whether administered orally, topically, parenterally, sublingually, etc.
In practice the present invention will involve ideally oral self administration of effective quantities of cetyl myristate alone or more preferably as a mixture of both cetyl myristate and cetyl palmitate.
Preferably in any such mixture the cetyl myristate comprises at least about half of the mixture or the serial application on a weight to weight basis. It is envisaged that daily doses will vary depending on patient needs and may range from 1 to 20 capsules per day. A capsule ideally contains between 5 to 370 mg of the mixture or cetyl myristate.
Trials with a variety of patients reliant upon dosage forms of cetyl myristate alone have shown favourable responses insofar as relief from the symptoms of heφes simplex is concerned. It has been found however that enhanced benefits occur where there is at least a small proportion of cetyl palmitate in addition to the cetyl myristate and it is to the use of one such ratio of these active ingredients that the following trial examples relate.
Examples of use follows. Each briefly describes the patient's condition before and after the stated treatment using dosage forms (ie; "of the invention") each having about 350 mg of the mixture of cetyl myristate and cetyl palmitate. That mixture comprises by weight 95% cetyl myristate and 5% cetyl palmitate by weight manufactured by the process as disclosed in NZ Patent Specification No. 332959. In addition added excipients were present in the non gelatin two part capsule case.
TRIAL EXAMPLES:
• Patient 1 is female and is 42 years of age.
Patient 1 suffers an acute flair of heφes simplex on her upper lip which results in deep lesions developing on her lip which is triggered by cold wind or sun exposure to her lips. In the past, this patient had used ZOVIRAX™ ointment.
At the first appointment Patient 1 was provided with capsules of a dosage unit as described in this invention for a dosage regime of 4 capsules, 3 times daily.
After two days Patient 1 noted that the lesion did not develop further and the tissue that did become affected was only superficial. The lesion then disappeared in about three days after taking the treatment.
• Patient 2 is female and is 39 years of age.
Patient 2 suffers acute heφes simplex virus on her lips. Again, this is triggered by cold wind or sun exposure to her lips. Again like patient 1, this patient has used ZOVIRAX™ ointment.
At the first appointment Patient 2 was provided with capsules of a dosage unit as described in this invention for a dosage regime of 4 capsules, 3 times daily. After one day the lesion did not develop any further and was also superficial as far as the lesion was concerned. • Patient 3 is male and is 43 years of age.
Patient 3 has suffered from Heφes simplex virus for 20 years. The virus attacks when the patient is run down and this is usually every 2-3 months. The symptoms begin with a common, itchy pain on the lip with the development of a lesion that can last up to 10-12 days. His treatment has included taking lysine amino acid as a dietary supplement.
At the first appointment Patient 3 was provided with capsules of a dosage unit as described in this invention for a dosage regime of 6 capsules, 3 times daily. This dosage begins when he sees the first symptoms of a heφes "pimple" and he continues with this dosage until the acute signs have disappeared.
After taking this dosage at a sufficiently early stage, the lesion in most cases had not developed. However, if it is taken at a later stage, such a large dose appears to interrupt the development of the lesion so that it is less extensive. Further the lesion caused disappeared after 4 days rather than the usual 10-12 days.

Claims

CLAIMS:
1. A method of treatment and/or prophylaxis of a mammal for at least the symptoms of heφes simplex which comprises or includes administering or having self administered to such mammal an effective amount of either
(a) cetyl myristate, or
(b) cetyl myristate and cetyl palmitate.
2. A method as claimed in claim 1 wherein said administration is orally of (b) whether as a mixture of both cetyl myristate and cetyl palmitate, or serially.
3. A method of claim 1 or 2 where the effective amount is of (b).
4. A method as claimed in claim 1 or 2 wherein said administration is with a mixture of cetyl myristate in conjunction with cetyl palmitate where the cetyl myristate comprises from 50 to 98% w/w of the mixture.
5. A method of any one of the preceding claims wherein said effective amount of (a) or (b) is by means of one or more capsules.
6. A method of any one of the preceding claims where both cetyl myristate and cetyl palmitate in admixture are administered, the ratio by weight to weight being 95:5 respectively.
7. A method of treatment of a human being for heφes simplex which comprises or includes having administered to that human an effective amount of cetyl myristate.
8. An oral pharmaceutical composition for treating at least the symptoms of heφes simplex which comprises or includes both cetyl myristate and cetyl palmitate.
9. A composition of claim 8 wherein said cetyl myristate comprises at least 50% by weight of the composition.
10. A composition of claim 8 or 9 which also includes at least one pharmaceutically acceptable excipient and/or diluent.
11. An oral dosage unit effective in the treatment of at least the symptoms of heφes simplex and/or, said dosage unit having either
(a) cetyl myristate, or
(b) a mixture of cetyl myristate and cetyl palmitate.
12. A dosage unit as claimed in claim 11 wherein said dosage unit has (b) and said cetyl myristate in any such mixture comprises from 50 to 98% w/w of the mixture.
13. A dosage unit as claimed in claim 11 wherein the dosage unit has (a) only and there is between 5 to 400 mg of cetyl myristate.
14. A dosage unit of claim 12 wherein there is from 5 to 400 mg of the mixture of cetyl myristate and cetyl palmitate.
15. A dosage unit of any one of claims 11 to 14 wherein (a) or (b) is in a capsule.
16. A dosage unit as claimed in claim 14 wherein said capsule also includes a pharmaceutically acceptable excipient and/or diluent.
17. A dosage unit of claim 14 which includes silicon dioxide.
18. A dosage unit of any one of claims 11 to 17 which also contains calcium phosphate and/or magnesium oxide.
19. A dosage umt of any one of claims 11 to 17 which also includes additionally at one trace element.
20. A liquid dosage composition or unit being also an oral composition of any one of claims 8 to 10 or an oral dosage unit as claimed in any one or claims 11 to 13 respectively.
21. The use, in the manufacture of oral dosage compositions or units for the treatment or prophylaxis of at least the symptoms of heφes simplex or related heφes skin ailments in a mammal, of
(a) cetyl myristate, or
(b) a mixture of cetyl myristate and cetyl palmitate, or
(c) cetyl palmitate.
22. The use, in the manufacture of oral dosage compositions or units for the treatment or prophylaxis of at least the symptoms of heφes simplex or related heφes skin ailments in a mammal, of
(i) cetyl myristate and (ii) cetyl palmitate.
23. The use of claim 21 wherein (b) is used.
24. The use of claim 23 wherein the ratio by weight of cetyl myristate to cetyl palmitate is 95:5.
25. A method of any one of claims 1 to 7 substantially as hereinbefore described with reference to the examples.
26. A dosage unit of any one of claims 11 to 20 substantially as hereinbefore described.
27. A composition of any one of claims 8 to 10 substantially as hereinbefore described.
28. The use of any one of claims 21 to 24 substantially as hereinbefore described.
PCT/NZ2001/000086 2000-05-12 2001-05-11 The treatment of herpes WO2001085164A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001260834A AU2001260834A1 (en) 2000-05-12 2001-05-11 The treatment of herpes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ504526A NZ504526A (en) 2000-05-12 2000-05-12 Treating herpes simplex symptoms using a mixture of cetyl myristate and cetyl palmitate
NZ504526 2000-05-12

Publications (1)

Publication Number Publication Date
WO2001085164A1 true WO2001085164A1 (en) 2001-11-15

Family

ID=19927882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2001/000086 WO2001085164A1 (en) 2000-05-12 2001-05-11 The treatment of herpes

Country Status (3)

Country Link
AU (1) AU2001260834A1 (en)
NZ (1) NZ504526A (en)
WO (1) WO2001085164A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147851B2 (en) 2000-05-12 2012-04-03 Lypanosys Pte Limited Treating eczema and/or psoriasis
EP2441441A1 (en) 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi A sieving method for cetyl myristate and/or cetyl palmitate
EP2441444A1 (en) 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Formulations of cetyl myristate and/or cetyl palmitate
EP2441445A1 (en) 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
EP2441446A1 (en) 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Using of superdisintegrants in cetyl myristate and/or cetyl palmitate formulations
EP2471528A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi A preparation method for suspension of cetyl myristate and/or cetyl palmitate
EP2471387A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Cetyl myristate and/or cetyl palmitate suspension formulations
EP2471384A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Suspension formulations of cetyl myristate and/or cetyl palmitate
EP2471385A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Cetyl myristate and/or cetyl palmitate suspension formulations
EP2471514A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Controlled moisture content of cetyl myristate and/or cetyl palmitate granules or formulations
EP2471386A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Cetyl myristate and/or cetyl palmitate suspension formulations
US8299120B2 (en) 2004-06-03 2012-10-30 Lypanosis Pte Limited Therapy for multiple sclerosis
EP2526931A1 (en) 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi Wet granulation methods of cetyl myristate and/or cetyl palmitate
EP2526936A1 (en) 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi Particle size distribution of cetyl myristate and/or cetyl palmitate

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2170407A (en) * 1985-02-05 1986-08-06 Sandoz Ltd Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
US5496565A (en) * 1993-03-16 1996-03-05 Beiersdorf Aktiengesellschaft Microspherules
WO1999056733A1 (en) * 1998-04-30 1999-11-11 Pharmatec International S.R.L. Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation
GB2337461A (en) * 1998-05-22 1999-11-24 Hewlett Healthcare Limited Formulations for topicval administration
WO1999060167A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
WO2000007627A2 (en) * 1998-08-04 2000-02-17 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
WO2000067728A2 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2170407A (en) * 1985-02-05 1986-08-06 Sandoz Ltd Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
US5496565A (en) * 1993-03-16 1996-03-05 Beiersdorf Aktiengesellschaft Microspherules
WO1999056733A1 (en) * 1998-04-30 1999-11-11 Pharmatec International S.R.L. Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation
WO1999060167A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
GB2337461A (en) * 1998-05-22 1999-11-24 Hewlett Healthcare Limited Formulations for topicval administration
WO2000007627A2 (en) * 1998-08-04 2000-02-17 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
WO2000067728A2 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147851B2 (en) 2000-05-12 2012-04-03 Lypanosys Pte Limited Treating eczema and/or psoriasis
US8586064B2 (en) 2000-05-12 2013-11-19 Lypanosys Pte Limited Treating eczema and/or psoriasis
US8535696B2 (en) 2000-05-12 2013-09-17 Lypanosys Pte Limited Treating eczema and/or psoriasis
US8299120B2 (en) 2004-06-03 2012-10-30 Lypanosis Pte Limited Therapy for multiple sclerosis
WO2012049642A1 (en) 2010-10-14 2012-04-19 Deva Holding Anonim Sirketi A sieving method for cetyl myristate and/or cetyl palmitate
WO2012049641A1 (en) 2010-10-14 2012-04-19 Deva Holding Anonim Sirketi Use of disintegrants in cetyl myristate and/or cetyl palmitate formulations
WO2012049639A1 (en) 2010-10-14 2012-04-19 Deva Holding Anonim Sirketi Formulations of cetyl myristate and/or cetyl palmitate
EP2441446A1 (en) 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Using of superdisintegrants in cetyl myristate and/or cetyl palmitate formulations
WO2012049640A1 (en) 2010-10-14 2012-04-19 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
EP2441441A1 (en) 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi A sieving method for cetyl myristate and/or cetyl palmitate
EP2441444A1 (en) 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Formulations of cetyl myristate and/or cetyl palmitate
EP2589378A1 (en) 2010-10-14 2013-05-08 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
EP2583673A1 (en) 2010-10-14 2013-04-24 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
EP2543364A1 (en) 2010-10-14 2013-01-09 Deva Holding Anonim Sirketi Formulations of cetyl myristate and/or cetyl palmitate
EP2441445A1 (en) 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
WO2012089762A1 (en) 2010-12-29 2012-07-05 Deva Holding Anonim Sirketi Cetyl myristate and/or cetyl palmitate granules having high bulk density
EP2471385A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Cetyl myristate and/or cetyl palmitate suspension formulations
WO2012089759A1 (en) 2010-12-29 2012-07-05 Deva Holding Anonim Sirketi Formulations of cetyl myristate and/or cetyl palmitate particles
WO2012089764A1 (en) 2010-12-29 2012-07-05 Deva Holding Anonim Sirketi A preparation method for suspension of cetyl myristate and/or cetyl palmitate
WO2012089763A1 (en) 2010-12-29 2012-07-05 Deva Holding Anonim Sirketi Separated formulations and granulations of cetyl myristate and cetyl palmitate combination
WO2012089765A1 (en) 2010-12-29 2012-07-05 Deva Holding Anonim Sirketi Suspension formulations of cetyl myristate and/or cetyl palmitate
EP2471386A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Cetyl myristate and/or cetyl palmitate suspension formulations
WO2012089761A1 (en) 2010-12-29 2012-07-05 Deva Holding Anonim Sirketi Controlled moisture content of cetyl myristate and/or cetyl palmitate granules or formulations
EP2471528A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi A preparation method for suspension of cetyl myristate and/or cetyl palmitate
EP2471387A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Cetyl myristate and/or cetyl palmitate suspension formulations
EP2471384A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Suspension formulations of cetyl myristate and/or cetyl palmitate
EP2471514A1 (en) 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi Controlled moisture content of cetyl myristate and/or cetyl palmitate granules or formulations
EP2526931A1 (en) 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi Wet granulation methods of cetyl myristate and/or cetyl palmitate
WO2012160050A2 (en) 2011-05-23 2012-11-29 Deva Holding Anonim Sirketi Particle size distribution of cetyl myristate and/or cetyl palmitate
WO2012160051A2 (en) 2011-05-23 2012-11-29 Deva Holding A.#. Wet granulation methods of cetyl myristate and/or cetyl palmitate
EP2526936A1 (en) 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi Particle size distribution of cetyl myristate and/or cetyl palmitate

Also Published As

Publication number Publication date
NZ504526A (en) 2003-05-30
AU2001260834A1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
JP5228185B2 (en) Krill and / or marine organism extracts for prevention and / or treatment of cardiovascular disease, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal delivery
US6696491B2 (en) Treating irritable bowel syndrome or disease
WO2001085164A1 (en) The treatment of herpes
CA2408541C (en) Treating eczema and/or psoriasis
AU2001260833A1 (en) Treating eczema and/or psoriasis
WO2003026640A1 (en) Treating food allergies and/or food intolerances
CN1126564C (en) Use of phospholipid complexes of extracts of i(vitis vinifera) as anti-atherosclerotic agent
AU2002343270B2 (en) Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties
US8586064B2 (en) Treating eczema and/or psoriasis
KR970705988A (en) (Preventive or remedy for diseases caused by abnormality of cartilaginous tissues caused by abnormalities in cartilage tissues)
NZ524311A (en) The treatment of herpes with cetyl myristate anad cetyl palmitate
NZ522434A (en) Treating eczema and/or psoriasis
NZ507229A (en) Treating food allergies
JP2000044470A (en) Hyperlipemia medicine
NZ522981A (en) Treating irritable bowel syndrome or disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP